Sharp optimizes FOCUS clinical supply chain to ensure zero waste

Focus study

Sharp has been the clinical trial partner of the University of Edinburgh since 2012, working closely with the teams to manage several long-running trials, including the Fluoxetine Or Control Under Supervision (FOCUS) trial. The FOCUS trial is a randomised controlled trial which aims to find out whether fluoxetine given to people for six months after a stroke improves long-term recovery, even if they do not have depression. The University of Edinburgh has been running the trial since August 2012, with recruitment closing in March 2017.

 

The Challenge Identified

 

As the study was nearing a close the Client determined that several sites which had already ceased patient recruitment had surplus clinical trial stock available. They approached Sharp Clinical for a solution that would allow the product to be redistributed and put to use at alternative sites. The intention was to minimize product waste.

 

The Sharp Solution

 

The Sharp project management team devised a strategy whereby Sharp arranged collection of the surplus stock from each of the sites and had it returned to Sharp where it would be collated, inspected and, if deemed suitable for use, returned to usable stock. The client was then able to request shipments from the surplus supplies to be dispatched to sites that needed it.

 

The Positive Impact

 

The client could make full use of all available supplies, right down to the last bottle, with zero wastage. Sharp has been working with this client since 2012 on four different projects. The relationship represents an excellent example of the customer partner collaboration that Sharp strives for and best illustrates our values of partnership and expertise.

 

The client was delighted with the partnership and Sharp’s involvement in the trial;

 

“A truly historic week with our last drug pack being dispatched. With Sharp’s help we have managed to ensure we had exactly the drug we needed to the very last pack!

 

Randomisation closed on the 31st March and the best news is that the trial target has been reached and surpassed so we are all very happy here.

 

Thank you so much for all your work on FOCUS. It’s been a real team effort and it has been a pleasure working with Sharp.”

 

The Sharp team responsible for delivering this clinical trial demonstrates the expertise and commitment that Sharp brings to our customers projects, from Quality Assurance to Project Management, in order to deliver the best solution for our client and their patients.

 

For more information on the FOCUS trial, click here.